Pyxis Oncology: FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC
PYX-201 has received fast track designation from the FDA for patients with recurrent or metastatic HNSCC following progression with chemoimmunotherapy.
Read full article »
Pyxis Oncology is a Massachusetts-based biotechnology company that researches and develops antibody therapeutics for the treatment of cancer.
Read more